Traded Apr 9 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
Traded Mar 11, 2026 · Filed Mar 12, 2026
The CEO of United Therapeutics sold $128K of United Therapeutics shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$128,032
Shares × reported transaction price
14 days after results of Feb 25, 2026, 56 days before results of May 6, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −1.1% | −0.9% | −0.1% |
| 30 days | +8.4% | +3.0% | +5.4% |
| 90 days | +2.1% | +8.9% | −6.8% |
| 180 days | −6.5% | +15.0% | −21.5% |
Past results only. Not a forecast.
Traded Apr 9 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
James Edgemond (CFO AND TREASURER) sold ~$322K of United Therapeutics
Scheduled in advanceJames Edgemond (CFO AND TREASURER) sold ~$1.13M of United Therapeutics
Scheduled in advance